the third day of the first wheezing episode and continued for at least 2 weeks. Terbutaline with the same delivery system was provided for as-needed use. Symptoms and ␤-agonist use were recorded daily for the 3 years of the study. One-hour study visits were conducted every 6 months. Nasal aspirates for viral culture and infant lung-function tests were monitored.
PURPOSE OF THE STUDY. To determine the role of inhaled corticosteroid (ICS) in preventing the development of asthma in a group of high-risk children before the development of symptomatic disease or abnormal lung function.
STUDY POPULATION. Subjects were 285 children aged 2 to 3 years at high risk for developing asthma.
METHODS. Subjects were assigned to fluticasone propionate (FP) 88 g twice per day with a pressurized metered-dose inhaler with spacer or placebo for a 2-year treatment period. The patients were observed without treatment for 1 year.
RESULTS. During the 2-year treatment period, there was significant improvement in symptom-free days for those in the FP group (86.8%-85.9%). Children in the FP group had more episode-free days, decreased exacerbations, and decreased need for extra controller medication. Those in the ICS group had a 1.1-cm decrement in growth after the first 2 years of the study, but this difference decreased to 0.7 cm after the 1-year observation period.
CONCLUSIONS. Although ICS had a significant effect on the burden of asthma during the treatment period, there was no evidence that a long-term effect was carried over to the 1-year observation period.
REVIEWER COMMENTS. The burden of childhood asthma is benefited with administration of ICS, but there is no evidence that long-term disease modification occurs. RESULTS. Fifty articles were identified on the initial search, and 17 of these randomized, double-blind, placebocontrolled studies (6 included adults and 11 included children) met the above-stated criteria. Eight studies compared ICSs with placebo, 3 compared ICSs plus systemic corticosteroids (SCSs) with SCSs, and 6 compared ICSs with SCSs. ICS doses used in the trials ranged from 400 g to 2 mg dispensed by inhaler or nebulizer, and the ICSs used included fluticasone (3 studies), budesonide (8), flunisolide (2), dexamethasone (1), and beclomethasone (3). "Multiple-dose" protocols administered Ն3 doses of ICS at Յ30-minute intervals, and "single-dose" protocols administered Յ2 doses at Յ30minute intervals or Ն1 dose at Ͼ30-minute intervals. Six studies examined the discharge rates 2 to 3 hours after multidose ICS treatment and found that a signifi-
